search
Back to results

Impact of FMT on the Phenome in Patients With NAFLD and Fibrosis

Primary Purpose

Non-Alcoholic Fatty Liver Disease, Fecal Microbiota Transplantation

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Faecal microbiota transplant
Sponsored by
Imperial College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Non-Alcoholic Fatty Liver Disease focused on measuring NAFLD, Gut microbiome, Metabolomics

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 18-75 years of age. Previously-diagnosed NAFLD, with predicted fibrosis based upon non-invasive assessment with FibroScan (i.e. liver stiffness measurement (LSM) > 8kPa). Raised liver ALT (> 30IU/l for men, > 19IU/l for women) or AST (> 37IU/l for men, > 31IU/l for women) with negative non-invasive liver screen (including negative screen for viral hepatitis, autoimmune liver disease and metabolic liver disease, and normal echocardiogram within two years in the scenario where congestive hepatopathy may be considered). Able to consent for themselves in English. Exclusion Criteria: Severe or life-threatening food allergy. Pregnant or lactating women; or women trying to conceive. Patients with suspected or confirmed cirrhosis (as assessed by clinical, radiological or histological criteria). Use of particular medications, including: Systemic antibiotics within the six weeks prior to study enrolment. Immunosuppression that may influence risks related to FMT (including - but not limited to: use of corticosteroids within eight weeks of intervention; use of cytotoxic chemotherapy; use of azathioprine, tacrolimus, mycophenolate mofetil and/or immunosuppressive biologic therapy, e.g. infliximab). Use of GLP-1 agonists. Patients not expected to survive the duration of the study's follow-up (six months). Swallowing difficulties that may preclude safe use of FMT capsules, including oral-motor dyscoordination. Alcohol consumption > 20g/ day. Any active cancer (including treatment within the past six months). Active infection at the point of recruitment, including COVID-19 infection. Prior receipt of a liver transplant. BMI < 23 in Asian potential participants and BMI < 25 in Caucasians. Advanced chronic kidney disease (eGFR < 30 ml/min). Chronic intestinal disease, including coeliac disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, and chronic diarrhoea. Prior bariatric surgery. Patients unable to undergo MRI scans (e.g. due to the individual having metallic implants).

Sites / Locations

  • Division of Digestive Diseases/ Liver Unit, St Mary's Hospital Campus, Imperial College LondonRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

NAFLD patients

Arm Description

Patients receiving capsulised FMT

Outcomes

Primary Outcome Measures

Change in faecal microbiome composition
Using 16S rRNA gene sequencing and shotgun metagenomic sequencing
Change in gut microbial metabolite composition
Using 1H-NMR and mass spectrometry

Secondary Outcome Measures

Changes in liver fat on MRI
Using MRI-PDFF
Changes in liver fat on FibroScan
Using CAP
Changes in liver stiffness on MRI
Using MRE
Changes in liver stiffness on FibroScan
Using transient elastography
Changes in HbA1c
Changes in insulin resistance
Combining fasting glucose and insulin levels to generate HOMA-IR
Changes in BMI
Through combination of measurement of weight in kilogram and height in metres, reporting BMI in kg/m^2
Changes in lipid metabolism
Serum lipid profile

Full Information

First Posted
August 23, 2023
Last Updated
August 29, 2023
Sponsor
Imperial College London
Collaborators
King's College London
search

1. Study Identification

Unique Protocol Identification Number
NCT06024681
Brief Title
Impact of FMT on the Phenome in Patients With NAFLD and Fibrosis
Official Title
Investigating the Impact of Faecal Microbiota Transplant on the Clinical Phenome of Patients With Non-alcoholic Fatty Liver Disease and Fibrosis
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 20, 2021 (Actual)
Primary Completion Date
September 29, 2023 (Anticipated)
Study Completion Date
May 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London
Collaborators
King's College London

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this pilot experimental medicine interventional study is to explore the degree of transferability of the gut microbiome and associated metabolomic changes in patients with non-alcoholic fatty liver disease (NAFLD) and fibrosis who receive faecal microbiota transplant (FMT). The main questions is aims to answer is: To what extent is the gut microbiome transferable from donor to recipient in patients with NAFLD with fibrosis who receive FMT? What are the dynamics of how the gut microbiome changes over time in these patients? To what degree does the recipient metabolome change in association with this? Participants will receive up to three capsulised FMT preparations prepared from a donor selected rationally based upon their metabolomic characteristics. They will be asked to attend for serial clinical assessments (including FibroScan and MRE/ MRI-PDFF), and will also be asked to provide serial blood, urine and stool samples for assessment of microbiome and metabolome profiling.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Alcoholic Fatty Liver Disease, Fecal Microbiota Transplantation
Keywords
NAFLD, Gut microbiome, Metabolomics

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Human participants with NAFLD and fibrosis
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NAFLD patients
Arm Type
Experimental
Arm Description
Patients receiving capsulised FMT
Intervention Type
Other
Intervention Name(s)
Faecal microbiota transplant
Intervention Description
Capsulised faecal microbiota transplant prepared from rationally selected donor, based upon donor metabolomic charateristics
Primary Outcome Measure Information:
Title
Change in faecal microbiome composition
Description
Using 16S rRNA gene sequencing and shotgun metagenomic sequencing
Time Frame
24 weeks after initial FMT
Title
Change in gut microbial metabolite composition
Description
Using 1H-NMR and mass spectrometry
Time Frame
24 weeks after initial FMT
Secondary Outcome Measure Information:
Title
Changes in liver fat on MRI
Description
Using MRI-PDFF
Time Frame
16 weeks after initial FMT
Title
Changes in liver fat on FibroScan
Description
Using CAP
Time Frame
16 weeks after initial FMT
Title
Changes in liver stiffness on MRI
Description
Using MRE
Time Frame
16 weeks after initial FMT
Title
Changes in liver stiffness on FibroScan
Description
Using transient elastography
Time Frame
16 weeks after initial FMT
Title
Changes in HbA1c
Time Frame
24 weeks after initial FMT
Title
Changes in insulin resistance
Description
Combining fasting glucose and insulin levels to generate HOMA-IR
Time Frame
24 weeks after initial FMT
Title
Changes in BMI
Description
Through combination of measurement of weight in kilogram and height in metres, reporting BMI in kg/m^2
Time Frame
24 weeks after initial FMT
Title
Changes in lipid metabolism
Description
Serum lipid profile
Time Frame
24 weeks after initial FMT

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18-75 years of age. Previously-diagnosed NAFLD, with predicted fibrosis based upon non-invasive assessment with FibroScan (i.e. liver stiffness measurement (LSM) > 8kPa). Raised liver ALT (> 30IU/l for men, > 19IU/l for women) or AST (> 37IU/l for men, > 31IU/l for women) with negative non-invasive liver screen (including negative screen for viral hepatitis, autoimmune liver disease and metabolic liver disease, and normal echocardiogram within two years in the scenario where congestive hepatopathy may be considered). Able to consent for themselves in English. Exclusion Criteria: Severe or life-threatening food allergy. Pregnant or lactating women; or women trying to conceive. Patients with suspected or confirmed cirrhosis (as assessed by clinical, radiological or histological criteria). Use of particular medications, including: Systemic antibiotics within the six weeks prior to study enrolment. Immunosuppression that may influence risks related to FMT (including - but not limited to: use of corticosteroids within eight weeks of intervention; use of cytotoxic chemotherapy; use of azathioprine, tacrolimus, mycophenolate mofetil and/or immunosuppressive biologic therapy, e.g. infliximab). Use of GLP-1 agonists. Patients not expected to survive the duration of the study's follow-up (six months). Swallowing difficulties that may preclude safe use of FMT capsules, including oral-motor dyscoordination. Alcohol consumption > 20g/ day. Any active cancer (including treatment within the past six months). Active infection at the point of recruitment, including COVID-19 infection. Prior receipt of a liver transplant. BMI < 23 in Asian potential participants and BMI < 25 in Caucasians. Advanced chronic kidney disease (eGFR < 30 ml/min). Chronic intestinal disease, including coeliac disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, and chronic diarrhoea. Prior bariatric surgery. Patients unable to undergo MRI scans (e.g. due to the individual having metallic implants).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Benjamin H Mullish, MB Chir PhD
Phone
+442033126454
Email
b.mullish@imperial.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pinelopi Manousou, MD PhD
Organizational Affiliation
Imperial College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Division of Digestive Diseases/ Liver Unit, St Mary's Hospital Campus, Imperial College London
City
London
ZIP/Postal Code
W2 1NY
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claire Parsonage
First Name & Middle Initial & Last Name & Degree
Mark R Thursz, MD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Only anonymised microbiome and metabolome data will be shared with other researchers via open access repositories

Learn more about this trial

Impact of FMT on the Phenome in Patients With NAFLD and Fibrosis

We'll reach out to this number within 24 hrs